Our website uses cookies to ensure you get the best experience with the most relevant info provided

Cardiolyse was issued with a US patent for its proprietary Method of ECG evaluation

One of Cardiolyse product core technologies for the unique Method of ECG Evaluation to deliver personalized cardiac risk assessment has been issued with the US patent!

The patent covers the invention of the Universal ECG Score, which is designed to diagnose the cardiovascular system based on at least 148 quantitative ECG parameters rating and aggregation. The score calculated provides the diagnostic and prognostic decision on the functional cardiovascular system state and psycho-emotional state, proven to increase the accuracy and reliability of the diagnostics.

It's exciting news and we're glad the innovative proprietary algorithms developed by our preeminent scientific team are now globally recognized and protected.

More to come on our way of expanding the Cardiolyse comprehensive heart signal processing and analysis platform worldwide

Back to blog

Related posts

Cardiolyse is the WINNER of the AMGEN Challenge of 2020 EIT Health Startups Meet Pharma

Microsoft for Startups $120K Azure Sponsorship Offer Received

Cardiolyse has been accepted to the OpenAPI Bootcamp

Cardiolyse is selected for the AMGEN Challenge of 2020 EIT Health Startups Meet Pharma event

Cardiolyse has won $50K in funding from Ukrainian Startup Fund

Read more

Let’s work together
on heart health improvement